Labiotech.eu

News and Trends 23 Jun 2022

Evaxion Biotech picks candidate for lung cancer trial

A clinical-stage biotech company that specializes in developing AI-driven immunotherapies has chosen its product candidate for an upcoming clinical trial for patients with advanced lung cancer. Evaxion Biotech selected EVX-03 within its DNA technology platform to target a new indication based on what it said are very encouraging results from pre-clinical studies. EVX-03 is optimized […]

June 23, 2022 - 2 minutesmins - By Liza Laws

News and Trends 23 Jun 2022

Antheia gets funding to build biomanufacturing plant

Antheia, a U.S. synthetic biology company enabling next-generation plant-inspired medicines, has announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank. The company also unveiled plans to construct a new pilot scale biomanufacturing facility. The financing will support Antheia’s expansion with a 14,700 square-foot pilot plant located next to Antheia’s […]

June 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Jun 2022

Osivax gets €10M influenza vaccine grant

A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to support a vaccine against influenza. The biopharma company develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases. It announced today (June 23) that it has secured the funds from Bpifrance to support the further clinical development […]

June 23, 2022 - 2 minutesmins - By Liza Laws

News and Trends 23 Jun 2022

Scancell to produce and clinically validate T cell redirecting bispecific antibodies

Scancell Holdings plc, which develops immunotherapies for the treatment of cancer and infectious disease, has announced it will develop its GlyMab antibodies into T cell redirecting bispecific (TCB) antibodies and take them into the clinic. The UK company said this is a promising new therapeutic approach to treat cancer. TCB antibodies have dual-binding specificity, which […]

June 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2022

Krystal Biotech looks for FDA approval for dystrophic epidermolysis bullosa treatment

U.S. gene therapy company Krystal Biotech, Inc, has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) for the treatment of patients with dystrophic epidermolysis bullosa (DEB). B-VEC is an investigational non-invasive, topical gene therapy designed to treat DEB at the molecular level by […]

June 23, 2022 - 3 minutesmins - By Jim Cornall

asia pacific biotech investment 2022 may 1

In Depth 23 Jun 2022

The biggest Asia-Pacific biotech investments in May 2022

Healthcare-focused biotech companies won the biggest private investments in the Asia-Pacific region in May 2022, led by a $100 million Series A from the Chinese anti-inflammatory drug developer Reistone Biopharma. In the Asia-Pacific region, Chinese biotechs generally took home the biggest private funding rounds in May 2022. The top rank went to Reistone Biopharma, located […]

June 23, 2022 - 3 minutesmins - By Jonathan Smith

shutterstock irritable bowel syndrome IBS

News and Trends 23 Jun 2022

Gemelli Biotech to work on gastrointestinal diseases with new $19M funding

U.S.-headquartered Gemelli Biotech Corp, which focuses on precision diagnostics for gastrointestinal (GI) diseases, has completed a $19 million series A finance round. Blue Ox Healthcare Partners, a private equity firm providing growth capital to companies targeting precision health and value-based care, led the investment round, joined by founding investor Cedars-Sinai, along with Carolina Angel Network, […]

June 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2022

BRIM Biotechnology enters OTC trading in Taiwan

BRIM Biotechnology, Inc.has entered OTC (over the counter) trading in Taiwan. Established in July 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. The company’s current paid-in capital is approximately $23 million. BRIM has several novel drug products in its pipeline, all underpinned by […]

June 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2022

Shanghai biotech secures $80 million to advance products

A bio-manufacturing company based in Shanghai has bagged $80 million in funding to advance its bio-based supplies. Mojia Biotech said it would use the funds to commercialize its Viridimin brand of animal-feed additives, scale up manufacturing capacity for Aliphane series of bio-based materials, advance its product pipeline and expand its global research and development capabilities. […]

June 23, 2022 - 2 minutesmins - By Liza Laws

covid-19 vaccine bottles, manufacture supply line, vaccine development

How a global network accelerated the development of a virus-like particle vaccine against Covid-19

Vaccines are among the most effective ways to improve and protect human health. Whereas vaccines in Europe and North America are regarded as part of the general medical plan, vaccine supply has always been a pressing issue in African countries. In the current Covid-19 pandemic, the ability to develop and manufacture vaccines in Africa instead […]

June 23, 2022 - 5 minutesmins - By Ute Boronowsky

News and Trends 22 Jun 2022

Roquefort Therapeutics buys UK biotech in return for shares

Medical biotechnology company, Roquefort Therapeutics, has conditionally agreed to buy UK biotech Oncogeni Ltd in return for shares. Oncogeni develops novel patented cancer medicines, and will receive 50 million shares, worth just under £4 million ($4.9 million). Acquisition In light of the acquisition, Oncogeni co-founder Ajan Reginald will become chief executive of the group, and […]

June 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Jun 2022

Millions invested for progression of Lyme disease vaccine

Pfizer has agreed to invest €90.5 million ($95 million) towards a vaccination for Lyme disease. A deal has been struck with Valneva SE that will see the start of the phase 3 study of the disease’s vaccine candidate, VLA15. This is scheduled for the third quarter of this year. The investment will represent 8.1% of […]

June 22, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Evaxion Biotech picks candidate for lung cancer trial

Antheia gets funding to build biomanufacturing plant

Osivax gets €10M influenza vaccine grant

Scancell to produce and clinically validate T cell redirecting bispecific antibodies

Krystal Biotech looks for FDA approval for dystrophic epidermolysis bullosa treatment

The biggest Asia-Pacific biotech investments in May 2022

Gemelli Biotech to work on gastrointestinal diseases with new $19M funding

BRIM Biotechnology enters OTC trading in Taiwan

Shanghai biotech secures $80 million to advance products

How a global network accelerated the development of a virus-like particle vaccine against Covid-19

Roquefort Therapeutics buys UK biotech in return for shares

Millions invested for progression of Lyme disease vaccine

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!